Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Down 28.7% in March

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 50,200 shares, a decline of 28.7% from the February 29th total of 70,400 shares. Based on an average trading volume of 93,300 shares, the short-interest ratio is presently 0.5 days. Approximately 0.5% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

APTO has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and set a $23.00 price target on shares of Aptose Biosciences in a report on Wednesday. Piper Sandler cut their target price on Aptose Biosciences from $12.00 to $5.00 and set an “overweight” rating on the stock in a report on Thursday, February 1st. Finally, StockNews.com upgraded Aptose Biosciences from a “sell” rating to a “hold” rating in a research note on Thursday. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Aptose Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $19.80.

Aptose Biosciences Trading Up 10.7 %

NASDAQ:APTO opened at $1.66 on Friday. Aptose Biosciences has a 1 year low of $1.36 and a 1 year high of $9.90. The firm’s fifty day simple moving average is $1.82 and its 200 day simple moving average is $2.35.

Institutional Investors Weigh In On Aptose Biosciences

Hedge funds have recently bought and sold shares of the company. Sequoia Financial Advisors LLC bought a new position in shares of Aptose Biosciences in the first quarter worth about $27,000. Texas Capital Bank Wealth Management Services Inc acquired a new stake in Aptose Biosciences in the 4th quarter valued at approximately $32,000. Cetera Advisors LLC grew its holdings in Aptose Biosciences by 40.1% in the 4th quarter. Cetera Advisors LLC now owns 86,827 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 24,847 shares during the last quarter. Millennium Management LLC increased its position in Aptose Biosciences by 75.4% in the 4th quarter. Millennium Management LLC now owns 222,930 shares of the biotechnology company’s stock worth $129,000 after buying an additional 95,796 shares during the period. Finally, Citadel Advisors LLC lifted its holdings in shares of Aptose Biosciences by 256.6% during the fourth quarter. Citadel Advisors LLC now owns 61,875 shares of the biotechnology company’s stock worth $155,000 after buying an additional 44,522 shares during the last quarter. 26.62% of the stock is currently owned by institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.